APA (7th ed.) Citation

Modi, S., Ates, O., Baird, R., Bulat, I., Moreno Candilejo, I., Curigliano, G., . . . Shao, Z. (2025). 621TiP BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC). Annals of Oncology, 36, S465. https://doi.org/10.1016/j.annonc.2025.08.1043

Chicago Style (17th ed.) Citation

Modi, S., et al. "621TiP BNT323-03: A Phase I/II Trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 X VEGF-A) in Patients (pts) with Advanced Breast Cancer (BC)." Annals of Oncology 36 (2025): S465. https://doi.org/10.1016/j.annonc.2025.08.1043.

MLA (9th ed.) Citation

Modi, S., et al. "621TiP BNT323-03: A Phase I/II Trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 X VEGF-A) in Patients (pts) with Advanced Breast Cancer (BC)." Annals of Oncology, vol. 36, 2025, p. S465, https://doi.org/10.1016/j.annonc.2025.08.1043.